<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18557" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>BRCA1 and BRCA2 Mutations</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Casaubon</surname>
            <given-names>Jesse T.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kashyap</surname>
            <given-names>Sarang</given-names>
          </name>
          <aff>Beckley Appalachian Regional Healthcare Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Regan</surname>
            <given-names>John-Paul</given-names>
          </name>
          <aff>St. Joseph's Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jesse Casaubon declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sarang Kashyap declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>John-Paul Regan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>23</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18557.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Breast cancer genes BRCA1 and BRCA2 are tumor suppressor genes whose mutations significantly increase the likelihood of developing particular types of epithelial malignancies, namely breast and ovarian cancer. The management of patients with a BRCA1 and BRCA2 gene mutations is individualized and can include increased surveillance, chemoprevention using tamoxifen, a bilateral prophylactic oophorectomy, and/or bilateral prophylactic mastectomy. This activity describes the etiology, epidemiology, pathophysiology, screening, evaluation, and management of BRCA 1 and 2 mutations and shows the importance of the interprofessional team in educating patients about the risk of cancer and management strategy for such patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of cancers associated with BRCA 1 and 2 mutations.</p></list-item><list-item><p>Outline the clinical presentation of patients with BRCA 1 and 2 mutations.</p></list-item><list-item><p>Explain the screening, monitoring, and treatment strategies in patients with BRCA 1 and 2 mutations.</p></list-item><list-item><p>Describe how an interprofessional team can collaborate to improve the diagnosis, monitoring, evaluation, and management of this condition and educate patients about the risk of cancer with BRCA 1 and 2 mutations.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/viewarticle/18557/?utm_source=pubmed&#x00026;utm_campaign=CME&#x00026;utm_content=18557">Earn FREE continuing education credits (CME/CE) on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18557.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>One in 8 women (12.5%) in the United States will develop breast cancer throughout their lifetime. Certain populations are at an increased risk of developing cancer due to genetic or hereditary predisposition. Breast cancer genes <italic toggle="yes">BRCA1&#x000a0;</italic>and&#x000a0;<italic toggle="yes">BRCA2</italic>&#x000a0;are tumor suppressor genes whose mutations significantly increase the likelihood of developing particular types of epithelial malignancies, namely breast and ovarian cancer <xref ref-type="bibr" rid="article-18557.r1">[1]</xref><xref ref-type="bibr" rid="article-18557.r2">[2]</xref>. Genetic or hereditary factors, including <italic toggle="yes">BRCA</italic> 1 and 2 mutations,&#x000a0;have been found to be&#x000a0;responsible for between 5% to 10% of breast cancer cases overall <xref ref-type="bibr" rid="article-18557.r3">[3]</xref>. Hereditary breast and ovarian cancer syndrome (HBOC) due to <italic toggle="yes">BRCA1 </italic>and&#x000a0;<italic toggle="yes">BRCA2&#x000a0;</italic>gene mutation is inherited in an autosomal dominant fashion and makes up roughly half of the cancer cases related to inherited genetic risk <xref ref-type="bibr" rid="article-18557.r4">[4]</xref>.</p>
        <p>The recognition of a genetic predisposition to cancer, knowledge of&#x000a0;risk patterns in&#x000a0;high-risk patients,&#x000a0;and access to testing have all&#x000a0;improved in recent years. Because of this, the ability to identify patients at risk, screen early, and prevent cancer have gained increased attention. The management of patients with a proven mutation of the <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> genes is individualized and can include&#x000a0;increased surveillance, chemoprevention using tamoxifen, bilateral prophylactic oophorectomy and or bilateral prophylactic mastectomy <xref ref-type="bibr" rid="article-18557.r5">[5]</xref>.</p>
        <p>Two common cancers linked to the presence of BRCA1 and BRCA2 include ovarian and breast cancers.</p>
      </sec>
      <sec id="article-18557.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The incidence of <italic toggle="yes">BRCA1</italic> or&#x000a0;<italic toggle="yes">BRC</italic><italic toggle="yes">A2</italic> mutations within the general population is infrequent and only found in 1 out of every 300 to 800 people <xref ref-type="bibr" rid="article-18557.r6">[6]</xref>. Certain populations exhibit&#x000a0;a higher likelihood of harboring genetic mutation than the general population. These include Ashkenazi Jewish patients, male patients who develop breast cancer, and patients younger than 30 years old who develop breast cancer. Founder mutations are particular mutations passed down between family members descendant from the same genetic lineage.&#x000a0;The specific mutations found in members of Ashkenazi Jewish lineage include 185delAG and 5385insC in the <italic toggle="yes">BRCA1</italic> genes and 6174delT in the <italic toggle="yes">BRCA2</italic> gene at a rate of 1 in 40 <xref ref-type="bibr" rid="article-18557.r6">[6]</xref>.</p>
        <p>While the risk for the development of breast cancer&#x000a0;is the highest of the epithelial malignancies (between 40% to 80%), the likelihood of developing other cancers including ovarian, pancreatic, and prostate is also increased in patients with <italic toggle="yes">BRCA1</italic> and&#x000a0;<italic toggle="yes">BRCA2</italic>&#x000a0;mutations <xref ref-type="bibr" rid="article-18557.r7">[7]</xref>.</p>
      </sec>
      <sec id="article-18557.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The normal risk for cancer development in the general population is 12.5% for female breast cancer, 0.1% for male breast cancer and 1% to 2% for ovarian cancer <xref ref-type="bibr" rid="article-18557.r2">[2]</xref><xref ref-type="bibr" rid="article-18557.r4">[4]</xref>. The incidence and associated risk for cancer development by age 70 for <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> mutations are listed below <xref ref-type="bibr" rid="article-18557.r8">[8]</xref><xref ref-type="bibr" rid="article-18557.r9">[9]</xref>.</p>
        <p>
<bold><italic toggle="yes">BRCA 1 </italic>Mutation</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Responsible for approximately 35% of hereditary breast cancer</p>
          </list-item>
          <list-item>
            <p>Increased risk of developing breast cancer by age 70 to 44% to 78%</p>
          </list-item>
          <list-item>
            <p>Increased risk of developing ovarian cancer by age 70 to 18% to 54%</p>
          </list-item>
          <list-item>
            <p>Increased risk of developing male breast cancer by age 70 to 0.22 to 2.8%</p>
          </list-item>
        </list>
        <p>
<bold><italic toggle="yes">BRCA 2</italic> Mutation&#x000a0; &#x000a0; &#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Responsible for approximately 25% of hereditary breast cancer</p>
          </list-item>
          <list-item>
            <p>Increased risk of developing breast cancer by age 70 to 31% to 56%</p>
          </list-item>
          <list-item>
            <p>Increased risk of developing ovarian cancer by age 70 to 2.4% to 19%</p>
          </list-item>
          <list-item>
            <p>Increased risk of developing male breast cancer by age 70 to 3.2% to 12%</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18557.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Tumor suppressor genes are integral for normal tissue growth control. These genes encode proteins that function to limit proliferation. However, if the tumor suppressor genes are inactivated by a point mutation, deletion or loss of expression, there is no longer any restraint on tissue growth. Both BRCA1 and BRCA2 are thought to act as tumor suppressor genes. Over the decades, it has been shown that mutations in the BRCA genes can lead to the development of breast, ovarian, prostate and colon cancer. In excess of 100 discrete germline mutations in BRCA1 and BRCA2 have been identified. Over the lifetime, there is a very high penetrance of germline BRCA mutations.</p>
      </sec>
      <sec id="article-18557.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The United States Preventive Service Task Force recommends that primary care physicians evaluate women who are candidates for hereditary cancer genetic testing by inquiring about family history of breast, ovarian, tubal or other cancers during annual examinations. If questioning reveals increased risk, referral to a certified genetic counselor (CGC) for possible testing is indicated (Grade B recommendations). Certified genetic counselors and breast surgeons may also aid in the decision regarding tests for <italic toggle="yes">BRCA</italic> alone, or for different genetic mutations related to other hereditary cancers <xref ref-type="bibr" rid="article-18557.r5">[5]</xref>.</p>
        <p>BRCA1 mutations are seen in about 7% of families with multiple breast cancers and in about 40% of families with ovarian and breast cancer. BRCA2 mutations are found in 20% of families at high risk for ovarian and breast cancers but in less than 3% of women with earlt onset breast cancer. Other cancers associated with BRCA2 mutations include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pancreas</p>
          </list-item>
          <list-item>
            <p>Prostate</p>
          </list-item>
          <list-item>
            <p>Stomach</p>
          </list-item>
          <list-item>
            <p>Bile duct</p>
          </list-item>
          <list-item>
            <p>Gallbladder</p>
          </list-item>
          <list-item>
            <p>Melanoma</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18557.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>American Society of Breast Surgeons emphasizes the importance of thorough patient history and uses the following criteria (similar to the NCCN guidelines for genetic risk evaluation).</p>
        <p>Criteria for testing in patients <bold><italic toggle="yes">with</italic></bold> a personal history of breast cancer and one or more of the following (from the NCCN and the American Society of Breast Surgeons Consensus Guideline on Hereditary Genetic Testing) <xref ref-type="bibr" rid="article-18557.r4">[4]</xref><xref ref-type="bibr" rid="article-18557.r5">[5]</xref>:</p>
        <list list-type="order">
          <list-item>
            <p>Age of onset less than or equal to&#x000a0;50</p>
          </list-item>
          <list-item>
            <p>Triple negative tumor (ER-PR-HER2-) and age less than or equal to 60</p>
          </list-item>
          <list-item>
            <p>Ashkenazi Jewish heritage and breast cancer at any age</p>
          </list-item>
          <list-item>
            <p>Two or more primary breast cancer (either asynchronous, synchronous, bilateral, or multicentric)</p>
          </list-item>
          <list-item>
            <p>A first-degree relative with breast cancer diagnosed at age less than or equal to 50</p>
          </list-item>
          <list-item>
            <p>Two relatives on the same side of the family with breast cancer and/or pancreatic cancer</p>
          </list-item>
          <list-item>
            <p>Family or personal history of ovarian cancer, fallopian cancer, or primary peritoneal cancer</p>
          </list-item>
          <list-item>
            <p>Male breast cancer</p>
          </list-item>
          <list-item>
            <p>Known mutation carrier in the family</p>
          </list-item>
        </list>
        <p>Testing patients who have not been diagnosed with cancer is typically reserved for situations when the affected family member or members cannot be tested. Criteria for testing patients <bold><italic toggle="yes">without </italic></bold>a personal history of breast cancer&#x000a0;but with one or more of the following (from the NCCN and American Society of Breast Surgeons Consensus Guideline on Hereditary Genetic Testing) <xref ref-type="bibr" rid="article-18557.r5">[5]</xref>:&#x000a0;</p>
        <list list-type="order">
          <list-item>
            <p>A first-degree or second-degree relative with age onset of breast cancer less than or equal to 45</p>
          </list-item>
          <list-item>
            <p>Ashkenazi Jewish heritage and family history of breast cancer at any age</p>
          </list-item>
          <list-item>
            <p>Two or more primary breast cancer (either asynchronous, synchronous, bilateral, or multicentric) in a single family member</p>
          </list-item>
          <list-item>
            <p>Two or more relatives on the same side of the family with breast and/or pancreatic cancer</p>
          </list-item>
          <list-item>
            <p>Family or personal history of ovarian, fallopian, or primary peritoneal cancer</p>
          </list-item>
          <list-item>
            <p>Male breast cancer</p>
          </list-item>
          <list-item>
            <p>Known mutation carrier in the family</p>
          </list-item>
        </list>
        <p>In addition to the above criteria, likelihood or risk assessment models such as the BRCAPRO, BOADICEA, Penn II, and IBIS can also be used to determine whether a patient is at an increased risk for carrying BRCA mutations and thus indicate the need for genetic testing or referral to a genetic counselor or breast surgeon. Though these models estimate the risk of developing breast cancer, no particular test or level of risk determines the need for or against <italic toggle="yes">BRCA</italic> testing.</p>
      </sec>
      <sec id="article-18557.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Surveillance for Patients with <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic>&#x000a0;Mutations</bold>
</p>
        <p>An increased level of monitoring is mandatory for all patients with known BRCA mutations. The NCCN guidelines are widely accepted in the management of patients with BRCA mutation. The main goal of monitoring is early detection of malignancy and high-risk premalignant lesions. Early detection begins with breast awareness and self-breast examination beginning at age 18 and annual or semiannual clinical breast examination at age 25 (though neither of these has shown to benefit survival) <xref ref-type="bibr" rid="article-18557.r5">[5]</xref>.</p>
        <p>Breast MRI increases sensitivity from approximately 33% to approximately 80% sensitivity in the detection of malignancy in patients with a familial or hereditary predisposition and has proven especially useful in this younger subset of patients. According to the NCCN guidelines, annual screening breast MRI with contrast is recommended annually from age 25 to 29 if available, or mammogram annually, if not. From age 30 to 75, annual mammogram and MRI of the breast with contrast is performed <xref ref-type="bibr" rid="article-18557.r5">[5]</xref>.</p>
        <p>The treatment is personalized for each patient who is found to have a <italic toggle="yes">BRCA1</italic> or <italic toggle="yes">BRCA2</italic> mutation. This may include increased surveillance only, chemoprevention using tamoxifen or raloxifene, bilateral prophylactic salpingo-oophorectomy and or bilateral prophylactic mastectomy. Bilateral prophylactic mastectomy reduces the risk of developing breast cancer by 90% to 95% <xref ref-type="bibr" rid="article-18557.r10">[10]</xref>. Referral to a breast surgeon for discussion regarding the option of risk-reducing mastectomy is indicated.</p>
      </sec>
      <sec id="article-18557.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Breast abscesses and masses</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Breast cancer</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Breast fibroadenoma imaging</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ductal carcinoma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Duct ectasia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Fibrocystic disease</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hyalinized fibroadenoma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Inflammatory carcinoma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Mastitis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Papilloma</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18557.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients with <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic>&#x000a0;mutation experience worse breast cancer-specific survival when compared to <italic toggle="yes">BRCA-</italic>negative patients. <italic toggle="yes">BRCA1</italic> carriers have a worse overall survival than <italic toggle="yes">BRCA2</italic>&#x000a0;patients <xref ref-type="bibr" rid="article-18557.r11">[11]</xref>.</p>
        <p>Studies do show that women who carry BRCA mutations are more likely to develop secondary cancer - either in the same breast or the contralateral breast. For these women, prophylactic bilateral mastectomy is recommended. More important, studies show that women who do undergo surgery are less likely to die from breast cancer compared to women who were treated with unilateral mastectomy.</p>
      </sec>
      <sec id="article-18557.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Women who carry BRCA1 and BRCA2 mutations are at high risk for several types of cancers including breast, ovary, colon, stomach, pancreas, and gallbladder. Because technological advances have made identification of these gene mutations cost-effective, the goal is to identify women at risk. To prevent malignancies by BRCA mutations requires an interprofessional team dedicated to oncology.</p>
        <p>The United States Preventive Service Task Force recommends that primary care physicians and nurse practitioners evaluate women who are candidates for hereditary cancer genetic testing by inquiring about family history of breast, ovarian, tubal or other cancers during annual examinations. If questioning reveals increased risk, referral to a certified genetic counselor (CGC) for possible testing is indicated (Grade B recommendations). Certified nursing and clinician genetic counselors and breast surgeons may also aid in the decision regarding tests for&#x000a0;<italic toggle="yes">BRCA</italic>&#x000a0;alone, or for different genetic mutations related to other hereditary cancers&#x000a0;<xref ref-type="bibr" rid="article-18557.r5">[5]</xref>.</p>
        <p>Other clinicians who see female patients should always ask about the family history of cancer and determine if studies are needed to evaluate for the presence of BRCA mutations.</p>
        <p>A positive <italic toggle="yes">BRCA</italic> mutation indicates a higher likelihood of developing cancer but does not make or confirm the diagnosis of cancer. Subsequently, a negative <italic toggle="yes">BRCA</italic> test does not eliminate the risk of developing breast cancer from sporadic or other genetic causes.</p>
        <p>Finally, when a patient is identified with BRCA mutations, the team should hold a conference with the patient. The patient should be provided with all the latest information and choices of treatment. The patient's decision should be voluntary and without any due pressure from the clinicians to produce the best outcomes. [Level 5]</p>
      </sec>
      <sec id="article-18557.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18557&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18557">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/home/freecme/?utm_source=pubmed&#x00026;utm_campaign=FREECME&#x00026;utm_content=18557">Access free CME on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/brca1-and-brca2-mutations-breast-cancer-gene-mutations/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=18557">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18557/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18557">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18557.s13">
        <title>References</title>
        <ref id="article-18557.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosen</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Pishvaian</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Targeting the BRCA1/2 tumor suppressors.</article-title>
            <source>Curr Drug Targets</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-31</page-range>
            <pub-id pub-id-type="pmid">24387337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18557.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palma</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ristori</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ricevuto</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Giannini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gulino</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers.</article-title>
            <source>Crit Rev Oncol Hematol</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-23</page-range>
            <pub-id pub-id-type="pmid">16337408</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18557.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valencia</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Samuel</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Viscusi</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Riall</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Neumayer</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Aziz</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The Role of Genetic Testing in Patients With Breast Cancer: A Review.</article-title>
            <source>JAMA Surg</source>
            <year>2017</year>
            <month>Jun</month>
            <day>01</day>
            <volume>152</volume>
            <issue>6</issue>
            <fpage>589</fpage>
            <page-range>589-594</page-range>
            <pub-id pub-id-type="pmid">28423155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18557.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Petrucelli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Pal</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <chapter-title><italic>BRCA1-</italic> and <italic>BRCA2</italic>-Associated Hereditary Breast and Ovarian Cancer</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>1998</year>
            <month>9</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">20301425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18557.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daly</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Pilarski</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Buys</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Farmer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Garber</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Kauff</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kohlmann</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kurian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Litton</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Madlensky</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Merajver</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Offit</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pal</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Reiser</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shannon</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Swisher</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vinayak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Voian</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Weitzel</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Wick</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Wiesner</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Dwyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Darlow</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-20</page-range>
            <pub-id pub-id-type="pmid">28040716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18557.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levy-Lahad</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Catane</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eisenberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hornreich</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lishinsky</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shohat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Beller</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Lahad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Halle</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.</article-title>
            <source>Am J Hum Genet</source>
            <year>1997</year>
            <month>May</month>
            <volume>60</volume>
            <issue>5</issue>
            <fpage>1059</fpage>
            <page-range>1059-67</page-range>
            <pub-id pub-id-type="pmid">9150153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18557.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ford</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Easton</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Stratton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Narod</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goldgar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Devilee</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bishop</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lenoir</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chang-Claude</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sobol</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Teare</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Struewing</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Arason</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scherneck</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rebbeck</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Tonin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Neuhausen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barkardottir</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eyfjord</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ponder</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Gayther</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Zelada-Hedman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.</article-title>
            <source>Am J Hum Genet</source>
            <year>1998</year>
            <month>Mar</month>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>676</fpage>
            <page-range>676-89</page-range>
            <pub-id pub-id-type="pmid">9497246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18557.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antoniou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pharoah</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Narod</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Risch</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Eyfjord</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Hopper</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Loman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Olsson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Johannsson</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Borg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pasini</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Radice</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Manoukian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eccles</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Olah</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Anton-Culver</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Warner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lubinski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gronwald</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gorski</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tulinius</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Thorlacius</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eerola</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nevanlinna</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Syrj&#x000e4;koski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kallioniemi</surname>
                <given-names>OP</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Peto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lalloo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Easton</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.</article-title>
            <source>Am J Hum Genet</source>
            <year>2003</year>
            <month>May</month>
            <volume>72</volume>
            <issue>5</issue>
            <fpage>1117</fpage>
            <page-range>1117-30</page-range>
            <pub-id pub-id-type="pmid">12677558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18557.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tai</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Domchek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Parmigiani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Breast cancer risk among male BRCA1 and BRCA2 mutation carriers.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2007</year>
            <month>Dec</month>
            <day>05</day>
            <volume>99</volume>
            <issue>23</issue>
            <fpage>1811</fpage>
            <page-range>1811-4</page-range>
            <pub-id pub-id-type="pmid">18042939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18557.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ludwig</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Neuner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Geurts</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review.</article-title>
            <source>Am J Surg</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>212</volume>
            <issue>4</issue>
            <fpage>660</fpage>
            <page-range>660-669</page-range>
            <pub-id pub-id-type="pmid">27649974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18557.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baretta</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Mocellin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goldin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Olopade</surname>
                <given-names>OI</given-names>
              </name>
              <name>
                <surname>Huo</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>95</volume>
            <issue>40</issue>
            <fpage>e4975</fpage>
            <pub-id pub-id-type="pmid">27749552</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
